Dr. Coleman on Moving Immunotherapy Into Earlier Treatment Lines in Cervical Cancer

Video

Robert L. Coleman, MD, FACOG, FACS, discusses the potential to move immunotherapy into earlier lines of treatment in cervical cancer.

Robert L. Coleman, MD, FACOG, FACS, chief scientific officer of The US Oncology Network, discusses the potential to move immunotherapy into earlier lines of treatment in cervical cancer.

The introduction of immunotherapy to the cervical cancer paradigm has been welcome as limited treatment options are available to these patients. Looking to ongoing research, the field hopes to sequence immunotherapy earlier into treatment, Coleman explains.

For example, the concept of utilizing immunotherapy plus radiation therapy followed by maintenance therapy could be beneficial in the adjuvant and localized disease settings, Coleman explains. Throughout 2021, it is likely that data regarding this approach will read out. Moreover, as the treatment landscape of cervical cancer has been relatively stagnant in recent years, the potential to offer a new treatment approach to patients with cervical cancer is exciting, Coleman concludes.

Related Videos
Jason Efstathiou, MD, DPhil
Amin Nassar, MD
Phillip J. Koo, MD
Daniel Petrylak, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center
Ilyas Sahin, assistant professor, Medicine, Department of Medicine, Division of Hematology & Oncology, University of Florida College of Medicine
Bhagirathbhai Dholaria, MBBS, associate professor, medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Eric S. Christenson, MD
Debra L. Richardson, MD, FACS, FACOG